- Home
- TROO vs HURA Comparison
TROO vs HURA Comparison
Compare TROO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- HURA
- Stock Information
- Founded
- TROO 2005
- HURA 2009
- Country
- TROO Hong Kong
- HURA United States
- Employees
- TROO N/A
- HURA N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- HURA
- Sector
- TROO Technology
- HURA
- Exchange
- TROO Nasdaq
- HURA Nasdaq
- Market Cap
- TROO 151.5M
- HURA 131.8M
- IPO Year
- TROO N/A
- HURA N/A
- Fundamental
- Price
- TROO $1.37
- HURA $2.10
- Analyst Decision
- TROO
- HURA Strong Buy
- Analyst Count
- TROO 0
- HURA 2
- Target Price
- TROO N/A
- HURA $11.50
- AVG Volume (30 Days)
- TROO 42.3K
- HURA 189.5K
- Earning Date
- TROO 12-04-2025
- HURA 11-14-2025
- Dividend Yield
- TROO N/A
- HURA N/A
- EPS Growth
- TROO N/A
- HURA N/A
- EPS
- TROO N/A
- HURA N/A
- Revenue
- TROO $15,084,000.00
- HURA N/A
- Revenue This Year
- TROO N/A
- HURA N/A
- Revenue Next Year
- TROO N/A
- HURA N/A
- P/E Ratio
- TROO N/A
- HURA N/A
- Revenue Growth
- TROO 247.24
- HURA N/A
- 52 Week Low
- TROO $0.49
- HURA $1.56
- 52 Week High
- TROO $3.05
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- TROO 52.11
- HURA 47.48
- Support Level
- TROO $1.14
- HURA $1.56
- Resistance Level
- TROO $1.40
- HURA $1.99
- Average True Range (ATR)
- TROO 0.10
- HURA 0.21
- MACD
- TROO 0.01
- HURA -0.01
- Stochastic Oscillator
- TROO 68.14
- HURA 50.96
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.